Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
$4.94
-1.6%
$4.82
$1.00
$7.00
$43.80M0.416,808 shs13,939 shs
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
$3.03
+1.3%
$3.12
$1.75
$4.97
$41.90M1.0699,458 shs62,000 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$1.82
-10.8%
$1.21
$0.47
$4.49
$9.26M1.32437,608 shs44,875 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.51
-5.5%
$0.53
$0.39
$3.75
$36.66M-0.02694,725 shs430,393 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
0.00%-1.59%-1.40%+7.39%+231.54%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
0.00%-6.77%+5.57%+7.83%+302,999,900.00%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00%-14.55%+112.87%+121.95%+880.08%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
0.00%-18.31%-3.46%-8.42%-84.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.5518 of 5 stars
3.35.00.00.02.21.70.0
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
2.4458 of 5 stars
3.50.00.00.02.60.81.3
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.5707 of 5 stars
0.05.00.00.01.10.00.6
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.209 of 5 stars
3.55.00.00.02.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.50
Moderate Buy$12.00142.91% Upside
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
3.00
Buy$12.00296.04% Upside
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
2.00
HoldN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.00
Buy$7.331,337.63% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/A$1.04 per shareN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/A$4.86 per shareN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/A$4.43 per shareN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$1.03M35.59N/AN/A$0.06 per share8.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
-$12.54MN/A0.00N/AN/AN/AN/AN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$9.57M-$0.86N/AN/AN/AN/A-20.36%-18.09%11/12/2025 (Estimated)
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-$22.94M-$3.89N/AN/AN/A-123.06%-94.28%N/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$30.02M-$0.91N/AN/AN/AN/A-1,258.76%-97.97%11/13/2025 (Estimated)

Latest MTNB, ATHE, GRCE, and RANI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q1 2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$0.22-$0.21+$0.01-$0.21N/AN/A
8/7/2025Q2 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.19-$0.18+$0.01-$0.18N/AN/A
6/20/2025Q4 2025
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$0.23-$0.21+$0.02$0.01N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/AN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/A
3.84
N/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A
8.87
8.87
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A
5.53
5.53
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.75
0.54
0.54

Institutional Ownership

CompanyInstitutional Ownership
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.14%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
6.08%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11.77%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
30.19%

Insider Ownership

CompanyInsider Ownership
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
38.80%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
11.10%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
4.60%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
45.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
108.87 million5.43 millionNot Optionable
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A13.83 million12.29 millionN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
305.09 million4.60 millionN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
11071.87 million39.47 millionOptionable

Recent News About These Companies

RANI: Second Quarter Financial Results
Rani (RANI) Q2 Net Loss Improves 16%
Rani Therapeutics Holdings, Inc. (RANI) - Yahoo Finance
Rani Therapeutics strikes deal to issue new warrants
RANI: 1Q:25 Financial Results
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)
Rani Therapeutics management to meet virtually with Lake Street

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alterity Therapeutics stock logo

Alterity Therapeutics NASDAQ:ATHE

$4.94 -0.08 (-1.59%)
Closing price 08/29/2025 03:59 PM Eastern
Extended Trading
$5.00 +0.05 (+1.11%)
As of 08/29/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Grace Therapeutics stock logo

Grace Therapeutics NASDAQ:GRCE

$3.03 +0.04 (+1.34%)
As of 08/29/2025 04:00 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Matinas Biopharma stock logo

Matinas Biopharma NYSE:MTNB

$1.82 -0.22 (-10.78%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$1.81 -0.01 (-0.55%)
As of 08/29/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Rani Therapeutics stock logo

Rani Therapeutics NASDAQ:RANI

$0.51 -0.03 (-5.50%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$0.51 +0.00 (+0.18%)
As of 08/29/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.